Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2029-2035
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2029-2035.)
© 1999 American Heart Association, Inc.
Hypoxia/Hypoxemia-Induced Activation of the Procoagulant Pathways and the Pathogenesis of Ischemia-Associated Thrombosis
Shi-Fang Yan;
Nigel Mackman;
Walter Kisiel;
David M. Stern;
David J. Pinsky
From the Departments of Physiology and Cellular Biophysics, Surgery and
Medicine, College of Physicians and Surgeons of Columbia University, New York,
NY (S.-F.Y., D.M.S., D.J.P.), the Departments of Immunology and Vascular
Biology, The Scripps Research Institute and La Jolla Cancer Research
Foundation, La Jolla, CA (N.M.), and the Departments of Pathology and
Biochemistry, University of New Mexico School of Medicine, Albuquerque, NM
(W.K.).
Correspondence to Dr Shi-Fang Yan/Dr David J. Pinsky, Departments of Physiology and Cellular Biophysics, P&S 17-401, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, New York. E-mail djp5{at}columbia.edu
 |
Abstract
|
|---|
AbstractAlthough oxygen
deprivation has long been associated
with triggering of the
procoagulant pathway and venous thrombosis,
blood hypoxemia and stasis
by themselves do not lead to fibrin
formation. A pathway is outlined
through which diminished levels
of oxygen activate the
transcription factor early growth response-1
(Egr-1) leading to
de novo transcription/translation of tissue
factor in mononuclear
phagocytes and smooth muscle cells, which
eventuates in vascular fibrin
deposition. The procoagulant response
is magnified by concomitant
suppression of fibrinolysis by hypoxia-mediated
upregulation
of plasminogen activator
inhibitor-1. These data add a new facet
to the biology of
thrombosis associated with hypoxemia/stasis
and imply that interference
with mechanisms causing Egr-1 activation
in response to oxygen
deprivation might prevent vascular fibrin
deposition
occurring in ischemia without directly interfering
with other
pro/anticoagulant pathways.
Key Words: tissue factor hypoxia ischemia Egr-1 PAI-1
 |
Introduction
|
|---|
In the 1850s, Virchow described the association
between venous
thrombosis and a triad of contributing factors,
including hypercoagulability,
vascular damage, and vascular
stasis.
1 More recently, venous
stasis has been linked to
the rapid decline in intravascular
oxygen tension and thrombus
formation in veins of the lower
extremities.
2 3 4
Definition of mechanisms through which low
levels of oxygen cause blood
to clot has been more elusive.
The Wessler stasis model of venous
thrombosis,
5 6 in which
a rabbit vascular segment
(typically the jugular vein) is occluded
and a fibrin clot subsequently
forms after addition of a procoagulant,
demonstrated that acute lack of
blood flow and/or hypoxemia,
although necessary, were not sufficient,
at least acutely, to
trigger clot formation. Without inclusion of a
strong procoagulant
stimulus, such as activated clotting
factors (eg, Factors IXa,
Xa, or thrombin), fibrin deposition did not
occur. These observations
have been extended to different types of
vessels, and this has
led to the same conclusion; acute occlusion of
normal vessels
with their normal blood content does not by itself
promote fibrin
formation. This situation must be differentiated from
that of
an atherosclerotic or other pathologic vessel, in which
abundant
neointimal tissue factor, a maximal prothrombotic
stimulus,
is immediately exposed to blood contents, triggering rapid
coagulation.
In fact, the intact, healthy vessel wall has very low
levels
of tissue factor with an increasing gradient toward the
adventitia.
The cell type most uniformly accepted as being capable of
expressing
substantive amounts of tissue factor within the
intravascular
space in response to environmental stimuli is the
mononuclear
phagocyte, although polymorphonuclear leukocytes may
also contribute,
and endothelial cells have been shown
to produce tissue factor
in selected settings.
7 8 Thus it
may not be surprising that
a brief period of hypoxemia and/or stasis
alone in a normal
vessel are not sufficient to trigger fibrin
formation.
Nonetheless, links between thrombosis and hypoxemia/stasis have
remained strong even in the absence of mechanistic explanations.
Studies in a canine model of limb immobilization showed stasis to be
associated with a rapid fall in venous oxygen tension to virtually
undetectable levels in the affected extremity.2
Furthermore, hypoxemia was most severe in proximity to venous valve
cusps, and nascent thrombi appeared to form on the apparently intact
vessel wall at the parietal aspect of the valve cusp (this occurred
during the period of hypoxemia). These accumulations of fibrin
contained peripheral blood cells and erythrocytes and were
speculated to result from hypoxemia-induced perturbation of the vessel
wall. In fact, when untraumatized canine leg veins were exposed in vivo
to intermittent periods of hypoxemia and reoxygenation,
venous thrombi were shown to occur.9 Therefore,
although in selected circumstances hypoxemia alone is sufficient to
cause venous thrombosis, blood stasis results in ischemia that
is associated with a myriad of changes in the vascular
microenvironment, including diminished aerobic metabolism
and accumulation of waste products. Thus the ischemic
environment induces cell stress on many levels in addition to a
contribution resulting from diminished blood oxygen. Another setting in
which hypoxia has been considered to have a central role
concerns vascular perturbation in response to high altitude, termed
hypobaric hypoxia. Mountain climbing and other activities at
high altitude are associated with vascular dysfunction, both
prothrombotic events and increased vascular permeability (high altitude
pulmonary and cerebral edema),10 11 12 13 and these
have been recently documented in graphic detail in the lay
press.14
In the setting of ischemia, the most striking tissue
injury occurs during reperfusion when leukocytes pour into the
previously unperfused zone. We propose that mechanisms underlying
pathologic events whose consequences are exaggerated during reperfusion
are set in motion during the previous period of hypoxemia. An example
of this principle is the critical period during organ preservation,
when hypoxemia and stasis prime the graft vasculature for damage during
reperfusion.15 Such tissue injury occurring as soon as
blood flow to the graft is reestablished is limited by strategies to
diminish preservation-induced vascular dysfunction with more optimal
preservation solutions during the period of organ storage. Our brief
review will focus on mechanisms through which hypoxemia promotes fibrin
formation in vivo and the results of recent studies to elucidate the
bases for such activation of the procoagulant pathway.
 |
A Model of Hypoxia-Induced Fibrin Deposition
|
|---|
We have developed a model system to examine the effects of
hypoxia
on intravascular thrombus formation, and this system
has also
recently been adapted by others in studies of mechanisms of
hypoxia-induced
thrombosis.
16 17 In this model,
analysis of fibrin formation
can employ 3 complementary
techniques: morphological and immunoblotting
studies
with monospecific polyclonal antibody to a neoepitope
in fibrin
gamma-gamma chain dimers (other investigators have
used antibody to
human fibrin beta chains with similar ability
to detect murine
fibrin),
16 electron microscopy, and deposition
of
radioiodinated fibrinogen. After exposure to
hypoxia, vascular
fibrin deposition occurs within approximately
6 hours.
18 Immunostaining
shows close
association of fibrin deposits with the vessel wall
(Figure 1A

), compared with lack of fibrin
deposits in normoxic
controls (Figure 1B

). Electron microscopy
shows that immunoreactive
fibrin deposits from hypoxemic lung
vasculature display ultrastructural
properties of fibrin, especially
the 22-nm periodicity (Figures
1C

and 1D

). Consistent
with these observations, immunoblotting
using
fibrin-specific antibody and extracts from hypoxic lung
treated with
plasmin showed an immunoreactive band, whereas
none was seen in
normoxic controls or in hypoxic mice that had
been pretreated with
either hirudin or blocking antibody to
tissue factor.
18
These data indicate that hypoxia/hypoxemia
triggers a pathway
leading to fibrin deposition in the lung.

View larger version (130K):
[in this window]
[in a new window]
|
Figure 1. Fibrin deposition in pulmonary vasculature
from mice exposed to hypoxia or normoxia. Mice were exposed to
hypoxia (A), FiO2 of 6%, or maintained in
normoxia (B) for 8 hours, followed by administration of heparin before
killing. Tissue was immunostained with antifibrin antibody.
A and B, x600; L indicates vascular lumen; arrows, vascular
endothelium; and *, red blood cells. Electron
micrograph of hypoxic (16 hours) murine pulmonary vasculature
(C) showing endothelium, red blood cells (RBC),
platelet clumping (Plt), and platelet-associated fibrin
(arrow). Higher magnification (D) demonstrates 22.5 nm periodicity
characteristic of fibrin; length of black bar is 112 nm. C, x12 450;
D, x44 650. Adapted from reference 18.
|
|
 |
Hypoxia-Associated Expression of Tissue Factor
|
|---|
Because blocking antibody to tissue factor suppressed fibrin
accumulation
in hypoxic murine lung, it was likely that oxygen
deprivation
caused increased expression of tissue factor in
a compartment
exposed to circulating blood. One possibility was that
polymorphonuclear
leukocytes (PMN) became adherent to the hypoxemic
vessel wall
due to translocation of P-selectin to the cell
surface
15 or
cytokine-mediated upregulation of
intercellular adhesion molecule-1
expression.
19
Subsequent leukocyte activation could generate
reactive oxygen
intermediates, damaging the vessel wall and
causing exposure of tissue
factor in subendothelial layers of
the vessel wall.
However, antibody-induced depletion of PMNs
had no effect on fibrin
accumulation.
18 Another mechanism could
be increased
vascular permeability due to the direct effect
of hypoxia on
the endothelium or indirectly via
hemodynamic
changes (for example, pulmonary
hypertension). However, increased
vascular leakage in response to
hypoxia occurs at later times
and is not substantially
different within 8 hours of being subject
to the oxygen-deficient
environment, at which time fibrin deposition
was already
evident.
18 In contrast, antibody-induced depletion
of
monocytes did suppress fibrin deposition in hypoxic
lung,
18 suggesting that this cell type was likely to have
an integral
role in activation of the procoagulant pathway in this
setting.
This evidence led us to predict that monocytes were triggering
the
procoagulant pathway, probably by upregulating tissue factor,
and
platelets were subsequently amplifying procoagulant events.
To test this hypothesis, tissue factor expression in hypoxic
murine lung was analyzed.20 Northern
analysis showed
20-fold increased tissue factor transcripts
in hypoxic lung from wild-type animals compared with normoxic controls
(Figure 2A
). Immunohistochemical studies
demonstrated increased tissue factor in hypoxic lung, colocalized with
mononuclear phagocytes20 from wild-type mice, compared
with normoxic controls. In vitro studies confirmed that mononuclear
phagocytes placed in an hypoxic environment demonstrate transcriptional
upregulation of tissue factor mRNA.20 These data
implicating tissue factor expression in hypoxia-driven
thrombosis are especially provocative, given recent data
showing the important role tissue factor plays in maintaining normal
hemostasis. When tissue factor is expressed at very low levels in
genetically altered mice, they exhibit a hemorrhagic
tendency.21

View larger version (33K):
[in this window]
[in a new window]
|
Figure 2. Hypoxia-mediated induction of tissue
factor expression in murine lung and the role of egr-1. A, Egr-1 null
mice show reduced tissue factor induction. Mice (wild-type, +/+;
homozygous null mice, -/-) were subjected to normoxia (N) or
hypoxia (H; 6% oxygen), lungs were rapidly harvested, total
RNA was prepared, and Northern analysis (30 µg/lane of total
RNA) was performed with 32P-labeled cDNA for mouse tissue
factor (upper) or ß-actin (lower). Adapted from reference 20. B,
Hypoxia-inducible tissue factor expression is due to
transcriptional activation at Egr-1 sites. Transient cotransfection of
HeLa cells was performed using either pTF(-111/+14)Luc, pTF(EGR-1
m)Luc, pTF(SP1 m)Luc, or pTF(EGR-1 m/SP1 m)Luc, and
pCMV-ßgalactosidase. Cultures were transfected with each of the
indicated constructs using the lipofectamine procedure, and then cells
were exposed to normoxia (N) or hypoxia (H) for 5 hours.
Luciferase and ß-galactosidase activity were then determined, and
relative luciferase activity normalized for ß-galactosidase
activity. Adapted from reference 20.
|
|
In depth exploration of the mechanism by which hypoxia
increases tissue factor transcription led to the identification of
Egr-1 as the primary driving motif underlying hypoxia-induced
tissue factor transcription. These data are in concordance with recent
studies identifying an association between Egr-1 and vascular
injury.22 23 Using double-stranded DNA probes from the
tissue factor promoter, electrophoretic mobility shift assays with
extracts from mononuclear phagocytes showed an apparent increase in Egr
DNA binding activity with no change in the DNA binding activity for Sp1
sites. The most striking data were obtained using consensus probes for
Sp1 or Egr-120 ; nuclear extracts showed no increase in the
gel shift band with Sp1 in response to hypoxia. In contrast,
similar experiments with the radiolabeled consensus Egr probe showed a
gel shift band (supershifted with antiEgr-1 antibody) in nuclear
extracts from hypoxic cultures, although not in normoxic counterparts.
Finally, transient transfection experiments were performed with
constructs promoter-reporter gene constructs derived from the serum
response region of the tissue factor promoter (Figure 2B
). Increased expression of the luciferase reporter was seen
with the wild-type construct, in which Sp1 and Egr-1 sites were intact,
whereas mutational inactivation of Egr-1 sites blocked
hypoxia-enhanced gene expression. Inactivation of Sp1 sites
prevented both basal and hypoxia-induced expression of
luciferase. Transfection studies with various promoter-luciferase
reporter constructs showed that only constructs with an intact Egr site
displayed increased expression in hypoxia.20 These
data emphasized the role of Egr-1 in hypoxia-modulated
expression of tissue factor.
In vivo studies confirmed the biological importance of
Egr-1driven tissue factor transcription by hypoxia;
homozygous Egr-1 null animals placed in a hypoxic environment showed a
much smaller increment in tissue factor mRNA, with virtually no change
in tissue factor antigen (Figure 2A
) and virtually no fibrin
deposition compared with their counterparts left in a normoxic
environment.20 Studies are in progress to trace the
sequence of events increasing Egr-1 activation in hypoxia, and
preliminary results indicate that oxygen deprivation
enhances de novo Egr-1 synthesis and that this is driven by binding of
ternary complex factor to ets/SRE sites in the Egr-1
promoter.24
 |
Hypoxia-Associated Suppression of Fibrinolysis
|
|---|
The unusual presence of fibrin within the intravascular
space
in hypoxic mice, even with an apparently intact
endothelial
cell lining, suggested that in addition to
enhanced procoagulant
activity, oxygen deprivation might
also be associated with diminished
fibrin removal. Our first studies
evaluating possible hypoxia-associated
suppression of
anticoagulant mechanisms focused on thrombomodulin.
25
However, hypoxia-mediate suppression of thrombomodulin
expression
was not observed until at least 24 hours subjecting cultures
to
oxygen deprivation,
25 and fibrin deposition
had already occurred
in the pulmonary vasculature by this time.
In contrast, analysis
of the fibrinolytic system has shown
coordinated enhanced expression
of plasminogen
activator inhibitor-1 (PAI-1) and suppression
of
plasminogen activators.
26 Use
of mice deficient in PAI-1, urokinase-type
plasminogen activator (uPA),
or tissue-type plasminogen activator
(tPA) provided definitive
evidence for the relevance of suppressed
fibrinolysis
to hypoxia-induced fibrin deposition. Whereas PAI-1
null mice
showed no increase in fibrin formation on exposure
to hypoxia,
uPA or tPA deficient mice showed a strong potentiation
of fibrin
deposition (Figures 3A

to 3C

). Thus PAI-1
overexpression
is likely to be an important factor preventing normally
active
fibrinolytic mechanisms from removing fibrin deposits formed
in
hypoxemic vasculature. In concordance with these data, mice
placed
under conditions of normobaric hypoxia showed increased
levels
of PAI-1 transcripts in the lung and, at the protein
level, increased
PAI-1 antigen and activity levels compared
with normoxic
controls.
26 Immunocytochemical analysis of cells
overexpressing
PAI-1 in hypoxic lung pointed to an important
contribution of
mononuclear phagocytes
18 (Figure 3D

). Further studies on hypoxic
lung showed a time-dependent
decrease in transcripts for tissue-type
urokinase-typeplasminogen
activators, lending
support to the concept that net fibrinolytic
activity of the hypoxic
lung was decreased, thereby facilitating
fibrin accumulation. The
results of in vitro studies using transformed
murine
macrophages (RAW cells) as a model system for
mononuclear
phagocytes pointed to a strong effect of hypoxia on
mononuclear
phagocytes. RAW cells showed a 6-fold increase in PAI-1
transcription
(by densitometric analysis of nuclear run blots)
after placement
in hypoxia. In addition to an increased rate of
transcription
of the PAI-1 message, there was also an apparent increase
in
the stability of the PAI-1 message under conditions of
hypoxia.
These 2 observations, the increased rate of PAI-1 mRNA
transcription
and the increased stability of the PAI-1 mRNA after
transcription,
contributed to the marked increase in PAI-1 mRNA in
hypoxic
cells, which was observed by Northern
analysis.
26

View larger version (60K):
[in this window]
[in a new window]
|
Figure 3. A to D, Role of fibrinolytic genes in
hypoxia-induced fibrin formation. A to C, Effect of deletion of
either the PAI-1 gene, the tPA gene, or the uPA gene on the
hypoxia-induced accumulation of
125I-fibrinogen/fibrin. At the onset of the 16-hour hypoxic
period, 125I-labeled murine fibrinogen was injected into
control mice or mice that were homozygous null for either the PAI-1gene
(A); the tPA gene (B); or the uPA gene (C). Relative deposition of
125I fibrinogen/fibrin was calculated as the ratio of cpm/g
tissue between hypoxic experimental and control animals, with a
relative value of 1 representing approximately a 3.5-fold
increase in the hypoxic/normoxic accumulation of 125I-FIB;
the modulating effect of a given gene on the hypoxia-induced
accumulation of 125I-FIB deposition is shown. Means±SEM
are shown. *P<0.05 and **P<0.01 versus
control. D, Immunohistochemical colocalization of PAI-1 antigen and
mononuclear phagocytes in lung tissue from normoxic and hypoxic (PAI-1
+/+) mice. Tissue was obtained from mice under normoxic conditions
(left panels) or after 16 hours exposure to normobaric hypoxia
(FiO2 5% to 6%, right panels). Adjacent sections of
paraffin-embedded tissue was immunostained for either PAI-1
(lower panels) or the mononuclear phagocyte marker F4/8041
(upper panels). In hypoxic lung tissue, cells that stain as
macrophages (arrows) stain strongly for the PAI-1 antigen (deep
russet color). Magnification, x400. Adapted from reference 26.
|
|
 |
Conclusion/Hypothesis
|
|---|
The adaptive response to hypoxia occurs on many levels.
Transcriptional
activation has been shown to involve
hypoxia-inducible factor
1 (HIF-1), AP-1, NF-kB, and in
the current work, Egr-1. The
best studied of these is HIF-1, first
identified during studies
to elucidate the basis for erythropoietin
expression stimulated
in response to oxygen deprivation.
Subsequently, HIF-1 has been
shown to mediate other critical facets of
the host response
to hypoxia, including upregulation of
glycolytic enzymes,
27 28 29 the noninsulin-dependent
glucose transporter,
the key angiogenic mediator vascular
endothelial growth factor,
and enzymes contributing to
vasomotor control, such as nitric
oxide and heme oxygenase
type I. In addition, HIF-1 has an essential
role in vasculogenesis, as
illustrated by the phenotype of HIF-1
null mice; complete
absence of HIF-1 alpha results in developmental
arrest, neural tube and
cardiovascular defects, and embryonic
lethality by day
11.
30 Activation of AP-1 in response to reductive
stress
has been shown in vitro and results in expression of
c-fos,
31 32 33 34 although assessment of the in vivo
significance of
these events has not yet been provided. Nuclear
translocation
of NF-kB has been observed by some groups,
35
although this
may be cell-type specific, as others have not observed
it.
31 Again, the
physiological/pathophysiological
implications of
NF-kB activation for adaptive mechanisms to
hypoxia have not
yet been clarified in vivo.
Previous in vitro studies suggested a central role for Egr-1 in
multiple cellular homeostatic events. Initially, Egr-1 was believed to
play a role in macrophage differentiation,36
although this has been called into question by a more recent
report.37 These possibilities were markedly drawn into
focus after production of Egr-1 null mice, which appear to
develop normally, and have only shown a phenotype after
environmental stress. For example, female Egr-1 null mice are sterile
due to luteinizing hormone-ß deficiency, an effect due to decreased
transcription of the gene. Our studies have shown a central role for
Egr-1 in monocyte expression of tissue factor after induction of
hypoxia. In view of the multiple stimuli that have been shown
to activate Egr-1, an immediate-early gene, it is unlikely that
oxygen deprivation directly induces activation of Egr-1.
Rather, hypoxic stress is likely to generate conditions leading to
Egr-1 activation and triggering of downstream mechanisms, including
tissue factor transcription-translation. In contrast to the apparently
positive impact of HIF-1mediated events on adaptation to
hypoxia, the beneficial effects of tissue factor expression in
monocytes and smooth muscle cells are less clear. Although local
promotion of clotting would serve to isolate an ischemic area,
the negative impact of vascular fibrin deposition eventuating in
occlusive thrombosis can have obvious deleterious consequences. Egr-1
expression in hypoxia might be predicted to impact on cell-cell
interactions through changes in the expression of cell adherence
molecules and inflammatory mechanisms through effects on
proinflammatory cytokines,38 although definite
proof of Egr-1 involvement in these events remains to be tested in
Egr-1 null mice. Thus Egr-1-initiated mechanisms may subserve a quite
different facet of the adaptive response to oxygen
deprivation compared with that associated with HIF-1.
However, recognition of a role for Egr-1 in potentially pathologic
changes associated with hypoxia could point to novel approaches
to limiting these events, ie, preventing activation of coagulation in
hypoxia by suppressing Egr-1 activation rather than by
interfering directly with the procoagulant mechanism.
The data presented in our brief review provide the
outline of a pathway through which hypoxia triggers de novo
expression of tissue factor in mononuclear phagocytes and smooth muscle
cells (Figure 4
). Lungs, which possess
tissue-based (alveolar) macrophages in great abundance, are
likely to recruit even more macrophages to intravascular
locations through expression of the monocyte chemoattractant
JE/monocyte chemoattractant protein-1 (MCP-1).
Hypoxia-associated activation of Egr-1 causes transcription and
subsequent cell surface expression of tissue factor in both vascular
smooth muscle cells and macrophages, which can initiate the
local procoagulant response. Further amplification of the amount of
fibrin deposited could be due to alterations in the balance of
fibrinolytic mediators, such as may occur by increased expression of
plasminogen activator inhibitor-1,
thereby attenuating removal of vascular fibrin. It might be expected
that any prothrombotic tendency, such as that in mice that have a
targeted point mutation in the thrombomodulin gene,16
would display an enhanced procoagulant response in this model. Thus
patients with the Factor V Leiden mutation, those deficient in protein
S, or those with other defects manifest as diminished
endogenous antithrombotic activity would be vulnerable to
enhanced fibrin deposition at hypoxemic sites in the vasculature.

View larger version (109K):
[in this window]
[in a new window]
|
Figure 4. Schematic representation of events leading
to fibrin accumulation within hypoxemic blood vessels.
|
|
This initial picture of hypoxia-associated triggering of
the procoagulant pathway raises many questions. For example, by what
mechanisms are monocytes attracted and retained in hypoxemic
vasculature? In a previous study, we observed that hypoxia
increased transcripts for the macrophage chemoattractant
JE/MCP-1 in cultured endothelial cells35
and that JE/MCP-1 antigen was increased in hypoxic lung (Lawson et al,
unpublished observation, 1995). Thus it is possible that
endothelial production of JE/MCP-1 draws in
macrophages and serves as a cofactor in their activation and
retention. JE/MCP-1 produced by hypoxic endothelium
could also have an integral role in increased expression of tissue
factor levels observed in smooth muscle cells39 40 in
hypoxemic vasculature. Aside from these questions of the basic biology
of the procoagulant response, recognition of the relative vulnerability
of the lung to hypoxemia-associated fibrin deposition in the mouse may
also provide important insights. Although reasons for this are unclear,
the combination of the lung's rich vasculature and the intensity of
the vasoconstrictor response to hypoxia, in contrast to
vasodilation in the systemic circulation, may serve to magnify
activation of coagulation. Taken together, the series of events causing
expression of tissue factor in the hypoxemic vasculature, especially in
mononuclear phagocytes and smooth muscle cells, provides a new biologic
context to consider mechanisms underlying and possible interventions to
prevent pathologic thrombosis in settings of oxygen scarcity.
 |
Acknowledgments
|
|---|
This work was supported by grants from the United States Public
Health
Service (HL55397, HL59488, HL60900, HL42507, HL35246,
PERC)
and the Surgical Research Fund.
Received September 16, 1998;
accepted February 8, 1999.
 |
References
|
|---|
-
Virchow R. Gessamelte Abhandlungen zur
Wissenschaftlichen Medicin. Frankfurt: A M Von Meidinger Sohn;
1856:525520.
-
Hamer JD, Malone PC, Silver IA. The
pO2 in venous valve pockets: Its possible bearing
on thrombogenesis. Br J Surg. 1981;68:166170.[Medline]
[Order article via Infotrieve]
-
Malone P. A hypothesis concerning the aetiology of
venous thrombosis. Med Hypothesis. 1991;5:189201.
-
Malone PC, Morris CJ. The sequestration and
margination of platelets and leukocytes in veins during conditions
of hypokinetic and anaemic hypoxia: Potential significance in
clinical postoperative venous thrombosis. J Pathol. 1978;125:119129.[Medline]
[Order article via Infotrieve]
-
Millet J, Vaillot M, Theveniaux J, Brown NL.
Experimental venous thrombosis induced by homologous serum in the rat.
Thromb Res. 1996;81:497502.[Medline]
[Order article via Infotrieve]
-
Bara L, Bloch MF, Samama MM. A comparative study of
recombinant hirudin and standard heparin in the Wessler model.
Thromb Res. 1992;68:167174.[Medline]
[Order article via Infotrieve]
-
Folkman J. Seminars in Medicine of the Beth Israel
Hospital, Boston. Clinical applications of research on angiogenesis.
N Engl J Med. 1995;333:17571763.[Free Full Text]
-
Zhang Y, Deng Y, Wendt T, Liliensiek B, Bierhaus A,
Greten J, He W, Hach-Wunderle V, Waldherr R, Ziegler R, Mannel D, Stern
DM, Nawroth PP. Intravenous somatic gene transfer with
antisense tissue factor restores blood flow by reducing tumor necrosis
factor-induced tissue factor expression and fibrin deposition in mouse
meth-A sarcoma. J Clin Invest. 1996;97:22132224.[Medline]
[Order article via Infotrieve]
-
Hamer JD, Malone PC. Experimental deep venous
thrombogenesis by a non-invasive method. Ann R Coll Surg
Engl. 1984;66:416419.[Medline]
[Order article via Infotrieve]
-
Lewis DM, Bradwell AR, Shore AC, Beaman M, Tooke JE.
Capillary filtration coefficient and urinary albumin leak at
altitude. Eur J Clin Invest. 1997;27:6468.[Medline]
[Order article via Infotrieve]
-
Hultgren HN. High-altitude pulmonary edema:
Current concepts. Annu Rev Med. 1996;47:267284.[Medline]
[Order article via Infotrieve]
-
Severinghaus JW. Hypothetical roles of angiogenesis,
osmotic swelling, and ischemia in high-altitude cerebral edema.
J Appl Physiol. 1995;79:375379.[Abstract/Free Full Text]
-
Johnson TS, Rock PB. Current concepts. Acute mountain
sickness. N Engl J Med. 1988;319:841845.[Medline]
[Order article via Infotrieve]
-
Krakauer J. Into Thin Air: A Personal Account of
the Mount Everest Disaster. New York: Anchor Books; 1997.
-
Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas
TN, Johnson RC, Hynes RO, Heath M, Lawson CA, Stern DM.
Hypoxia-induced exocytosis of endothelial cell
Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment
after cardiac preservation. J Clin Invest. 1996;97:493500.[Medline]
[Order article via Infotrieve]
-
Weiler-Guettler H, Christie PD, Beeler DL, Healy AM,
Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD. A targeted point
mutation in thrombomodulin generates viable mice with a prethrombotic
state. J Clin Invest. 1998;101:19831991.[Medline]
[Order article via Infotrieve]
-
Healy AM, Hancock WW, Christie PD, Rayburn HB,
Rosenberg RD. Intravascular coagulation activation in a murine model of
thrombomodulin deficiency: Effects of lesion size, age, and
hypoxia on fibrin deposition. Blood. 1998;92:41884197.[Abstract/Free Full Text]
-
Lawson CA, Yan S-D, Yan S-F, Liao H, Chen G,
Sobel J, Kisiel W, Stern DM, Pinsky DJ. Monocytes and tissue factor
promote thrombosis in a murine model of oxygen deprivation.
J Clin Invest. 1997;99:17291738.[Medline]
[Order article via Infotrieve]
-
Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E,
Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, Burns DK,
Goldstein A, Stern D. Hypoxia-mediated induction of
endothelial cell interleukin-1a. An autocrine mechanism
promoting expression of leukocyte adhesion molecules on the vessel
surface. J Clin Invest. 1992;90:23332339.
-
Yan S-F, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL,
Milbrandt J, Pinsky D, Kisiel W, Stern D. Tissue factor transcription
driven by Egr-1 is a critical mechanism of murine pulmonary
fibrin deposition in hypoxia. Proc Natl Acad Sci
U S A. 1998;95:82988303.[Abstract/Free Full Text]
-
Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N.
Low levels of tissue factor are compatible with development and
hemostasis in mice. J Clin Invest. 1998;101:560569.[Medline]
[Order article via Infotrieve]
-
Khachigian LM, Lindner V, Williams AJ, Collins T.
Egr-1-induced endothelial gene expression: A common
theme in vascular injury. Science. 1996;271:14271431.[Abstract]
-
Khachigian LM, Williams AJ, Collins T. Interplay of Sp1
and Egr-1 in the proximal platelet-derived growth factor A-chain
promoter in cultured vascular endothelial cells.
J Biol Chem. 1995;270:2767927686.[Abstract/Free Full Text]
-
Yan S-F, Gao Y, Zhai C, Stern DM.
Hypoxia-triggered signal transduction mechanisms underlying
induction of tissue factor. Circulation. 1998;98:I-40.
-
Ogawa S, Shreeniwas R, Brett J, Clauss M, Furie
M, Stern DM. The effect of hypoxia on capillary
endothelial cell function: modulation of barrier and
coagulant function. Br J Haematol. 1990;75:517524.[Medline]
[Order article via Infotrieve]
-
Pinsky DJ, Liao H, Lawson CA, Yan S-F, Chen J,
Carmeliet P, Loskutoff DJ, Stern DM. Coordinated induction of
plasminogen activator inhibitor-1
(PAI-1) and inhibition of plasminogen activator
gene expression by hypoxia promotes pulmonary vascular
fibrin deposition. J Clin Invest. 1998;102:919928.[Medline]
[Order article via Infotrieve]
-
Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic
regulation of lactate dehydrogenase A. Interaction between
hypoxia-inducible factor 1 and cAMP response elements.
J Biol Chem. 1995;270:2102121027.[Abstract/Free Full Text]
-
Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional
regulation of genes encoding glycolytic enzymes by
hypoxia-inducible factor 1. J Biol Chem. 1994;269:2375723763.[Abstract/Free Full Text]
-
Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ.
Oxygen-regulated control elements in the phosphoglycerate kinase 1 and
lactate dehydrogenase A genes: Similarities with the erythropoietin 3'
enhancer. Proc Natl Acad Sci U S A. 1994;91:64966500.[Abstract/Free Full Text]
-
Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E,
Wenger RH, Gearhart JD, Lawler AM, Yu AY, Semenza GL. Cellular and
developmental control of O2 homeostasis by hypoxia-inducible
factor 1 alpha. Genes Dev. 1998;12:149162.[Abstract/Free Full Text]
-
Rupec RA, Baeuerle PA. The genomic response of tumor
cells to hypoxia and reoxygenation.
Differential activation of transcription factors AP-1 and NF-kappa B.
Eur J Biochem. 1995;234:632640.[Medline]
[Order article via Infotrieve]
-
Kerppola TK, Curran T. Maf and Nrl can bind to AP-1
sites and form heterodimers with Fos and Jun. Oncogene. 1994;9:675684.[Medline]
[Order article via Infotrieve]
-
Okuno H, Akahori A, Sato H, Xanthoudakis S, Curran T,
Iba H. Escape from redox regulation enhances the transforming activity
of Fos. Oncogene. 1993;8:695701.[Medline]
[Order article via Infotrieve]
-
Abate C, Curran T. Encounters with Fos and Jun on the
road to AP-1. Semin Cancer Biol. 1990;1:1926.[Medline]
[Order article via Infotrieve]
-
Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yan SD,
Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K, et al. Hypoxic
induction of interleukin-8 gene expression in human
endothelial cells. J Clin Invest. 1994;93:15641570.
-
Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B. The
zinc finger transcription factor Egr-1 potentiates macrophage
differentiation of hematopoietic cells. Mol Cell Biol. 1995;15:54995507.[Abstract]
-
Lee SL, Wang Y, Milbrandt J. Unimpaired
macrophage differentiation and activation in mice lacking the
zinc finger transplantation factor NGFI-A (EGR1). Mol Cell
Biol. 1996;16:45664572.[Abstract]
-
Khachigian LM, Collins T. Inducible expression of
Egr-1-dependent genes. A paradigm of transcriptional activation in
vascular endothelium. Circ Res. 1997;81:457461.[Free Full Text]
-
Schecter AD, Giesen PL, Taby O, Rosenfield CL,
Rossikhina M, Fyfe BSK, Fallon JT, Nemerson Y, Taubman MB. Tissue
factor expression in human arterial smooth muscle cells. TF
is present in three cellular pools after growth factor stimulation.
J Clin Invest. 1997;100:22762285.[Medline]
[Order article via Infotrieve]
-
Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT,
Rossikhina MG, Nemerson Y, Taubman MB. Tissue factor is induced by
monocyte chemoattractant protein-1 in human aortic smooth muscle and
THP-1 cells. J Biol Chem. 1997;272:2856828573.[Abstract/Free Full Text]
-
Lee S-H, Starky PM, Gordon S. Quantitative
analysis of total macrophage content in adult mouse
tissues. J Exp Med. 1985;161:475489.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
M. T. Pritchard, S. Roychowdhury, M. R. McMullen, L. Guo, G. E. Arteel, and L. E. Nagy
Early growth response-1 contributes to galactosamine/lipopolysaccharide-induced acute liver injury in mice
Am J Physiol Gastrointest Liver Physiol,
December 1, 2007;
293(6):
G1124 - G1133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sayasith, K. A Brown, J. G Lussier, M. Dore, and J. Sirois
Characterization of bovine early growth response factor-1 and its gonadotropin-dependent regulation in ovarian follicles prior to ovulation.
J. Mol. Endocrinol.,
October 1, 2006;
37(2):
239 - 250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Adhami, G. Liao, Y. M. Morozov, A. Schloemer, V. J. Schmithorst, J. N. Lorenz, R. S. Dunn, C. V. Vorhees, M. Wills-Karp, J. L. Degen, et al.
Cerebral Ischemia-Hypoxia Induces Intravascular Coagulation and Autophagy
Am. J. Pathol.,
August 1, 2006;
169(2):
566 - 583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Pozza and R. C. Austin
Getting a GRP on Tissue Factor Activation
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2005;
25(8):
1529 - 1531.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wang, S. Dostanic, N. Servant, and L. E. Chalifour
Egr-1 negatively regulates expression of the sodium-calcium exchanger-1 in cardiomyocytes in vitro and in vivo
Cardiovasc Res,
January 1, 2005;
65(1):
187 - 194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S Cherniack
Oxygen sensing: applications in humans
J Appl Physiol,
January 1, 2004;
96(1):
352 - 358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. von Kanel and J. E. Dimsdale
Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease
Chest,
November 1, 2003;
124(5):
1956 - 1967.
[Abstract]
[Full Text]
[PDF]
|
 |
|